Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Exp Pharmacol Physiol ; 43(1): 56-66, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26414003

ABSTRACT

Hyperglycemia induces all isoforms of transforming growth factor ß (TGFß), which in turn play key roles in inflammation and fibrosis that characterize diabetic nephropathy. Sphingosine 1-phosphate (S1P) is a signaling sphingolipid, derived from sphingosine by the action of sphingosine kinase (SK). S1P mediates many biological processes, which mimic TGFß signaling. To determine the role of SK1 and S1P in inducing fibrosis and inflammation, and the interaction with TGFß-1, 2 and 3 signalling in diabetic nephropathy, human proximal tubular cells (HK2 cells) were exposed to normal (5 mmol/L) or high (30 mmol/L) glucose or TGFß-1, -2, -3 ± an SK inhibitor (SKI-II) or SK1 siRNA. Control and diabetic wild type (WT) and SK1(-/-) mice were studied. Fibrotic and inflammatory markers, and relevant downstream signalling pathways were assessed. SK1 mRNA and protein expression was increased in HK2 cells exposed to high glucose or TGFß1,-2,-3. All TGFß isoforms induced fibronectin, collagen IV and macrophage chemoattractant protein 1 (MCP1), which were reversed by both SKI-II and SK1 siRNA. Exposure to S1P increased phospho-p44/42 expression, AP-1 binding and NFkB phosphorylation. WT diabetic mice exhibited increased renal cortical S1P, fibronectin, collagen IV and MCP1 mRNA and protein expression compared to SK1(-/-) diabetic mice. In summary, this study demonstrates that inhibiting the formation of S1P reduces tubulointerstitial renal inflammation and fibrosis in diabetic nephropathy.


Subject(s)
Diabetic Nephropathies/metabolism , Diabetic Nephropathies/pathology , Kidney Tubules/injuries , Kidney Tubules/metabolism , Lysophospholipids/metabolism , Sphingosine/analogs & derivatives , Animals , Biomarkers/metabolism , Cell Line , Diabetic Nephropathies/enzymology , Dose-Response Relationship, Drug , Enzyme Inhibitors/pharmacology , Extracellular Matrix/drug effects , Extracellular Matrix/metabolism , Extracellular Signal-Regulated MAP Kinases/metabolism , Fibrosis , Gene Expression Regulation, Enzymologic/drug effects , Gene Silencing , Glucose/pharmacology , Humans , Inflammation/enzymology , Inflammation/metabolism , Inflammation/pathology , Kidney Cortex/drug effects , Kidney Cortex/metabolism , Kidney Cortex/pathology , Kidney Tubules/drug effects , Kidney Tubules/pathology , Male , Mice , NF-kappa B/metabolism , Phosphoproteins/metabolism , Phosphotransferases (Alcohol Group Acceptor)/antagonists & inhibitors , Phosphotransferases (Alcohol Group Acceptor)/deficiency , Phosphotransferases (Alcohol Group Acceptor)/genetics , Phosphotransferases (Alcohol Group Acceptor)/metabolism , Sphingosine/metabolism , Transcription Factor AP-1/metabolism , Transforming Growth Factor beta/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...